Multivesicular liposomes for sustained release of bevacizumab in treating laser-induced choroidal neovascularization

Multivesicular liposomes for sustained release of bevacizumab in treating laser-induced choroidal neovascularization

Bevacizumab is an anti-vascular endothelial growth factor drug that can be used to treat choroidal neovascularization (CNV). Bevacizumab-loaded multivesicular liposomes (Bev-MVLs) have been designed and developed to increase the intravitreal retention time of bevacizumab and reduce the number of inj...

Full description

Bibliographic Details
Main Authors: Hongjie Mu, Yiyun Wang, Yongchao Chu, Ying Jiang, Hongchen Hua, Liuxiang Chu, Kaili Wang, Aiping Wang, Wanhui Liu, Youxin Li, Fenghua Fu, Kaoxiang Sun
Format: Article
Language:English
Published: Taylor & Francis Group 2018-01-01
Series:Drug Delivery
Subjects:
bevacizumab
choroidal neovascularization
multivesicular liposomes
bioactivity
intravitreal injection
vitreous humor
Online Access:http://dx.doi.org/10.1080/10717544.2018.1474967

Internet

http://dx.doi.org/10.1080/10717544.2018.1474967

Similar Items